Emblem Corp. (TSXV: EMC) (OTCQB: EMMBF) is a publicly traded, fully integrated Canadian medical and adult recreational cannabis company led by a team of proven senior executives with experience in the pharmaceutical industry, the cannabis horticulture industry and health care.
Emblem is an “indoor” cannabis producer, growing in six controlled environment indoor grow rooms at its facility in Paris, Ontario. A seventh grow room will be added by spring 2018, which will bring Emblem’s total capacity to 2,400 kilograms per year at a cost-effective 1.5 grams per watt.
Emblem is licensed by Health Canada to produce cannabis oils using super critical CO2 extraction technology. The company is currently completing an expansion that will provide about 30,000 square feet to house a GMP extraction laboratory, pharmaceutical production and value-added product facility. In preparation for the Canadian adult recreational cannabis market expected to rollout by July 2018, Emblem is planning to build a 115,000 square foot facility with an indoor capacity of 15,000 kilograms at 1.5 grams per watt.
Emblem has adopted a three-part strategy to the Canadian cannabis industry:
- Targeting medical cannabis by focusing on the development and sale of cannabinoid-based pharmaceutical formulations; Emblem expects that more advanced cannabis formulations will displace dried flower and simple oils in the Canadian medical market.
- Targeting the adult recreational cannabis market by distinguishing its product offerings through growing high quality indoor dried flowers and developing unique value-added, extraction-based products.
- Targeting education and healthcare by providing medical cannabis patients with information and resources not generally available from the Canadian healthcare system.
The likely addition of cannabis-infused edibles and other concentrates to Canada’s legalization plans for marijuana are expected to produce significant revenue streams for the company. An amendment to Bill C-45, otherwise known as the Canadian Cannabis Act, would ensure these derivatives of cannabis will be available no later than 12 months after the country officially legalizes recreational cannabis in July 2018.
Emblem has invested several million dollars into its Pharma division to research marijuana drug candidates and potential new drugs derived from cannabis. Over time, the company expects this division to be the largest and most profitable as it focuses initially on bringing drugs to market that will address neuropathic pain, anxiety and sleep issues. By providing standardized, consistent doses of cannabinoid-based pills and oils, Emblem intends to lead the industry. Value-added products such as sustained release and accelerated release formulations will materially increase product demand. Emblem’s focus on regulating the growth environment by using a holistic, organic method means each cannabis strain is healthy and true to its mother plant, which in turn assures a naturally grown, robust medical cannabis product.
Emblem, which had 2,154 active patients as of August 2017, continues to enroll patients in its GrowWise Health program which is also seeing a marked expansion of its clinic network. Projected growth in this sector, along with the value-added benefits provided for patients and physicians, is expected to ensure ongoing patient registration. Emblem plans to open additional GrowWise Health clinic locations across Canada.
Covering the full cannabis spectrum, Emblem’s business is structured to reach new heights from growing to selling recreational and medical cannabis, to educating and assisting patients, to creating new forms of cannabinoid-based medications in standardized, high quality and convenient-to-use formulations.